Skip to main content
Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy

Fig. 7

Gene-set tumor analysis of CSMD1 expression using 3520 breast cancer patients SCAN-B cohort. Box plot of CSMD1 gene expression for tumor samples of SCAN-B cohort stratified according to (A) clinical groups, (B) tumor grade (Nottingham Histological Grade) (C) PAM50 subtypes and (D) box plot of CSMD1 gene expression for tumor samples of SCAN-B cohort subset of TNBC stratified according to basal and non-basal like properties. Kaplan–Meier analysis, using (E) OS and (F) IDFS as endpoints, for TNBC patients treated with chemotherapy (n = 239) stratified into the two quantiles based on CSMD1 median gene expression level. Kaplan–Meier analysis, using (G) OS and (H) IDFS as endpoints, for TNBC patients treated with chemotherapy (n = 239) stratified into the four quantiles based on CSMD1 and EGFR median gene expression level

Back to article page